Talk:Panitumumab

This is the talk page for discussing improvements to the Panitumumab article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Wikipedia? Welcome! Learn to edit; get help.

Article policies

Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL

Pharmacology Mid‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Panitumumab.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Untitled

This is a brand new drug (just licenced in spetember 2006) similar to cetuximab, infact in theory it should be better. I will try and develop it when i have some time, but it would be silly to delete it. It is certainly not spam.StephP 23:29, 14 October 2006 (UTC)[reply]

I agree, it is notable, see [1]. Lincher 16:15, 20 October 2006 (UTC)[reply]

I think panitumumab is IgG2, not IgG1. Could the author please check? Thanks.

News to incorporate

Amgen's Vectibix effective in difficult-to-treat wild-type KRAS mCRC patients and extra background info - Rod57 (talk) 23:29, 25 January 2016 (UTC)[reply]